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Pulmonary Arterial Hypertension (PH)
is a chronic, progressive, and fatal
lung disease characterized by narrow-
ing of pulmonary arteries associated
with muscular thickening and intimal
proliferation, known as remodeling. If
untreated, the 5-year survival rate of
PH is 34% (McLaughlin et al., 2002).
Unfortunately, there is no systematic
strategy established to effectively man-
age this devastating disease. Currently,
the best curative option for PH is lung
transplantation. It, however, is applica-
ble for only a few patients mainly due
to the lack of suitable donors. Moreover,
even if lung transplantation is success-
fully performed, the patients have to
take immunosuppressant for the rest of
their life. Administration of long-term
immunosuppressant has been associ-
ated with high incidence of side effects
including severe and sometimes fatal
infections.
The FDA-approved medications for PH
fall into three categories: (i) prostacyclin
derivative, which is a very potent vasodila-
tor and also a inhibitor of pulmonary
artery smooth muscle cell (PASMC)
proliferation, (ii) endothelin-1 receptor
antagonist, which counteracts vasocon-
striction and PASMC proliferation, and
(iii) phosphodiesterase-5 inhibitor, which
causes pulmonary vasodilatation and inhi-
bition of PASMC proliferation. These
vasodilators have certainly achieved signif-
icant advances in the management of PH
during the last decade. However, because
of their short half-lifes and narrow ther-
apeutic ranges, close monitoring and/or
follow-up is required to avoid exces-
sive side effects involved in vasodilation.
Some PH patients with severe conditions
even require continuous intravenous or
subcutaneous administration of these
drugs, which can be a big clinical chal-
lenge for both patients and health care
providers. To get a better way in managing
PH conditions and in maintaining long-
term patient adherence, a new drug that
specifically and strongly blocks PASMC
proliferation, a key pathological event in
PH, is desired.
In the last decade, a good line of
evidence has revealed that there is a
variety of similarities existent between
PH and cancer (McMurtry et al., 2005;
Dromparis et al., 2010; Aljubran et al.,
2012). Two representatives of them are
uncontrolled cellular proliferation and
resistance to apoptosis. In the recent issue
of Circulation, Mouraret et al. present an
elegant study on the effects of Nutlin-3a
on PH (Mouraret et al., 2013). Nutlin-
3a, which is a cis-imidazoline analog,
was originally developed as an anti-cancer
drug. It stabilizes p53 by inhibiting the
binding of MDM2 (murine double minute
2), a p53-specific E3 ubiquitin ligase that
promotes p53 degradation (Vassilev et al.,
2004). p53, a representative tumor sup-
pressor protein, plays a critical role in
tumor suppression through several differ-
ent mechanisms primarily involving the
DNA repair process. Recently, it has been
reported that p53 deletion deteriorates
hypoxia-induced PH in mice (Mizuno
et al., 2011). Consistent with this report,
Mouraret et al. revealed that a p53 sta-
bilizer Nutlin-3a reversed PH in three
distinct experimental mouse models with
only limited side effects noted in con-
trol mice without PH. Moreover, they
confirmed that Nutlin-3a requires p53
and p21 expression to work as an anti-
PH drug showing that Nutlin-3a exerts
no effects on hypoxia-exposed p53−/−
and p21−/− mice. Intriguingly, the paper
also shows that Nutlin-3a treatment of
cultured human PASMCs results in cell
growth arrest but not apoptosis, which
is consistent with other reports using
fibroblasts frommice and humans (Efeyan
et al., 2007; Kumamoto et al., 2008).
Therefore, it appears that Nutlin-3a has
a totally different mechanism of action
from currently available drugs and that
it is not directly associated with relax-
ation of smooth muscle and vasodilation
of the pulmonary arteries, which lessens
the concern about the side effects related
to vasodilation. If Nutlin-3a works well for
treatment of PH patients and it becomes
an approved therapeutic application, PH
patients would be able to have more ther-
apeutic options including combination
therapies, which ultimately would lead to
decreased number of PH patients with
advanced stages. The benefit of expanded
therapeutic options could have an impact
in decreasing the number of PH patients
waiting for lung transplantation. On the
other hand, one minor drawback of using
Nutlin-3a as a potential PH treatment
is its slow clinical effect on the patients
with severe PH due to its lack of direct
vasodilatory effect. However, in spite of
the above mentioned disadvantage, this
new drug still has an enormous thera-
peutic potential for treatment of PH. The
day may come before long when Nutlin-
3a will come out as a blessing for PH
patients.
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